LIXTE BIOTECHNOLOGY HOLDINGS, INC.
LIXTCIK 0001335105 · Pharmaceutical Preparations · Nasdaq
- SRKP 7 INC (until 2006-12-01)
Revenue (TTM)
$0
Q1 May 2026
Net Income (TTM)
−$4.45M
−69.5% YoY
Q1 May 2026
EPS Diluted (TTM)
−$1.09
+20.8% YoY
Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
—
Q1 May 2026
Cash
$3.41M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
12.38M sh
Q1 May 2026
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
No data available for this metric.
Balance Sheet
Cash vs Debt
Latest news
All news →-
High Positive
LIXTE Biotechnology (LIXT) Loans $6.5M to NOMAD Ahead of Merger
LIXTE is lending $6.5 million to NOMAD Transportable Power Systems before their planned July 1 closing, with the combined company set to be renamed and trade un...